Our study consists of a population with a certain degree of homogeneity since the vast majority of the NSCLC patients received immunotherapy as a monotherapy with PD-1/PDL-1 inhibitors and most of the patients received it as 2nd line treatment. This evidence concerns the gene CD274 and non-small cell lung carcinoma.